UK green light for Valneva’s French vaccine without messenger RNA

[Article publié jeudi 14 avril 2022 à 11:15, mis à jour avec reprise de la cotation Bourse 13:45]

“The Covid-19 vaccine that Valneva has developed today has received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK regulator announced in its press release on Thursday.

The MHRA specifies that the United Kingdom is the first country in the world to approve the Franco-Austrian vaccine against Covid-19 developed by the Valneva laboratory.

“VLA2001 is currently the only vaccine candidate with inactivated and adjuvanted vaccines against COVID-19 in clinical development in Europe,” the laboratory in Saint-Herblin (Nantes) welcomed in its press release this morning.

However, the road to this success was fraught with many obstacles. Reminder: in September

the UK government had canceled a 1.4 billion euro supply contract with the Franco-Austrian lab that was to deliver 100 million doses of its vaccine that the UK ordered for him in February 2021. The title had fallen sharply by then. † Read:

Anti-Covid-19 vaccine: London ends its contract with Valneva, which plunges up to -44% into the stock market

Today, this authorization comes in addition to the permit Valneva received in March 2022 for the emergency use of its serum from the Kingdom of Bahrain, which purchased 1 million doses of it.

And the approval process by EU authorities is still ongoing, with the lab also signing an agreement with the European Commission to supply up to 60 million doses over two years in 2022 and 2023. In the UK, this approval process was conducted by the Independent Commission for Medicinal Products for Human Use and its Covid-19 Expert Task Force, which, after“carefully considered the available evidence” concluded that “the benefit/risk ratio is positive

said Professor Munir Pirmohamed, chairman of this committee, quoted in this press release.

A vaccine that can reassure mRNA-refractory substances

As for the scope of use of the Valneva vaccine: it can be used in people aged 18 to 50 years, the first and second doses should be taken at least 28 days apart.

Advantage, this vaccine can be stored at the temperature of conventional refrigerators, which facilitates its use. But the main advantage of this vaccine:

could be the design method, which aims to be “traditional”, based on inactivated virus technology, such as that used for classic flu vaccines, and which can reassure those who are resistant to vaccination, carried out with products designed according to the messenger RNA (mRNA) technology, from which they fear a poor assessment of hypothetical very long-term side effects. To get an idea of ​​the potential market for this vaccine, let’s take as an example the number not vaccinated in France that’s 5 million people, or that of Unvaccinated Germans

estimated to be between 12 and 15 million people at the end of 2021.

The UK strengthens its anti-Covid-19 arsenal

The United Kingdom is therefore strengthening its arsenal with a sixth vaccine against the coronavirus, after those of AstraZeneca, Pfizer, Moderna, the single-dose Janssen (Johnson & Johnson) and Novavax.

Regarding the controversy over the risks of thrombosis as a side effect of the AstraZeneca vaccine, which had been temporarily banned, the UK authorities had first explained that there was no increase in the risk of thrombosis in vaccinees compared to the general population. Nevertheless, this extremely rare risk was well identified and UK authorities funded research into its origins and operation. And in Dec 2021, the cause of this problem has been identified

and Astrazeneca’s lab says it’s been working on a solution to eliminate this very rare side effect ever since.

As a reminder, the UK has been hit hard by the coronavirus pandemic, which has killed more than 171,000 people. More than 92% of the population aged 12 years and older received a first dose of the Covid-19 vaccine, 86.2% a second dose and 67.8% a booster dose.The European Union has paid a heavy price for this pandemic with close 920,000 dead

of the coronavirus since early 2020. The global death toll has exceeded 6 million since 2020.

Share price rose 15% after suspension At the Paris stock exchange, very logical the action valneva

rose to 22% (about EUR 18.70) just after the resumption of trading at 11:30 GMT (1:30 pm, Paris time). The title was temporarily suspended at Valneva’s request before market opening pending the publication of the lab’s press release confirming the authorization. After that, the title fell little by little, bringing the increase to 10.91% (EUR 16.92) around 3.40 pm. As a reminder: the stock market performance of the Valneva has been particularly disturbed since announcing the launch of his vaccine: the action has lost 37.7% since the beginning of the following year

216% in 2021 and 202% in 2020.

(with AFP and Reuters)